Novartis Exelon® Patch now FDA approved to treat patients across all stages of Alzheimer's disease

[2013-06-27] - - Latest FDA approval based on high dose Exelon Patch 13.3 mg/24h for severe Alzheimer's; 24-week study showed statistically significant improvement in overall cognition and function compared to 4.6 mg/24h dose
- Exelon Patch first and only transdermal therapy approved to treat all stages of Alzheimer's
- More than five million Americans are living with Alzheimer's, a progressive disease with limited treatment options (1,2)
- Exelon Patch already approved for treatment of mild to moderate dementia of the Alzheimer's type and mild to moderate dementia associated with Parkinson's disease

Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer

[2013-06-03] - - Investigational compound LDK378 is a selective inhibitor of ALK1, a target found in metastatic non-small cell lung cancer (NSCLC)
- Data show 60% overall response rate in 78 patients with ALK+ NSCLC taking LDK378 at 750 mg; will serve as basis for first filing in early 2014
- FDA designated LDK378 as Breakthrough Therapy in March and a robust clinical development plan is underway

Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA

[2013-05-29] - - Latest Phase III research on Afinitor® in advanced HER2 positive breast cancer
- Jakavi™ overall survival advantage evaluated in three-year study in patients with myelofibrosis, a rare and life-threatening blood cancer
- Multi-year studies evaluating deep molecular response with Tasigna® in patients with Ph+CML
- Data from LDK378 trial in ALK+ metastatic non-small cell lung cancer; supports recent FDA Breakthrough Therapy designation

Most read: scientific news



Follow us...

google plus Facebook twitter Newsletter



Plan du site